Tradestie Institutional Equity Comparison Engine

DRMA vs CING โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CING Overall Edge

CING Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cingulate Inc. Common Stock (CING) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DRMA trades at N/M Forward P/E with -13082.3% operating margin (+0.0% YoY revenue) versus CING at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DRMA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DRMA N/M vs CING N/M Fwd P/E
Growth & Margin Winner CING
Op Margin -13082.3% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CING
1Y -81.2% vs +35.4% ยท 52W Pos 0% vs 18%
Options & Structure Winner CING
UNCLASSIFIED (N/A IV) vs BREAKDOWN (16th %ile IV)
DRMA NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-3.83% 1D
Market Cap $3.1M
1M Return -33.07%
1Y Return -81.25%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 33.0 Fund 46.0 Flow 50.0 Mom 60.0
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap $62.5M
1M Return +8.37%
1Y Return +35.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DRMA -81.25% CING +35.39% Spread: +116.64 pp (CING Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DRMA TTM Op. Margin: -13082.3% CING TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRMA vs CING. Trailing 12-month operating profitability (DRMA -13082.3% vs CING 0.0%) and valuation multiples (DRMA N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DRMA (1) vs CING (5)
Institutional Metric DRMA CING Criterion Row Winner
Market Capitalization Scale $3.1M $62.5M Larger Scale CING
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability -13082.3% 0.0% Higher Margin CING
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -241.5% -198.7% Higher ROE CING
52-Week Range Position Momentum 0% ($1โ€“$5) 18% ($3โ€“$12) Stronger Trend CING
Beta / 30D Volatility Risk Regime 1.13ฮฒ ยท 112% Vol 1.07ฮฒ ยท 121% Vol Lower Realized Risk DRMA
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite CING

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DRMA vs CING Buy Guide
DRMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DRMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DRMA nor CING registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.